You are correct that immutep may become a household name. You may or may not be correct on whether hotcopper is influencing management and share price. Regardless management has failed to produce share price results with enormous dilution. Even if/when this goes to market long term holders have been abandoned by management. Love the data but enormous misses by management in momentum building in the American market. Eftilagimod is worth 8-10 billion without approval in autoimmune. Without approval it should currently have a 1 billion dollar market cap given current data. Instead data and patents are only worth 50% of cash holdings. Remarkable failure yet i still hold long.
IMM Price at posting:
28.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)